Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye

Basit Öğe Kaydı
dc.authorscopusid57211837783
dc.authorscopusid55776027400
dc.authorscopusid56293113300
dc.authorscopusid56653318600
dc.authorscopusid57371520400
dc.authorscopusid57224985108
dc.authorscopusid57210186649
dc.contributor.authorTekinalp, A.
dc.contributor.authorGedük, A.
dc.contributor.authorAkdeniz, A.
dc.contributor.authorDemirsoy, E.T.
dc.contributor.authorGürsoy, V.
dc.contributor.authorAk, M.A.
dc.contributor.authorBağcı, M.
dc.date.accessioned2024-08-25T18:39:24Z
dc.date.available2024-08-25T18:39:24Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractObjective: This study aimed to evaluate patients with relapsed/ refractory multiple myeloma (RRMM) who underwent daratumumab (DARA) therapy. Materials and Methods: This multicenter retrospective study included 134 patients who underwent at least two courses of DARA from February 1, 2018, to April 15, 2022. Epidemiological, disease, and treatment characteristics of patients and treatment-related side effects were evaluated. Survival analysis was performed. Results: The median age at the start of DARA was 60 (range: 35-88), with 56 patients (41.8%) being female and 48 (58.2%) being male. The median time to initiation of DARA and the median follow-up time were 41.2 (5.1-223) and 5.7 (2.1-24.1) months, respectively. The overall response rate after DARA therapy was 75 (55.9%), and very good partial response or better was observed in 48 (35.8%) patients. Overall survival (OS) and progression-free survival (PFS) for all patients were 11.6 (7.8-15.5) and 8.0 (5.1-10.9) months, respectively. OS was higher for patients undergoing treatment with DARA and bortezomib-dexamethasone (DARA-Vd) compared to those undergoing treatment with DARA and lenalidomide-dexamethasone (DARA-Rd) (16.9 vs. 8.3 months; p=0.014). Among patients undergoing DARA-Rd, PFS was higher in those without extramedullary disease compared to those with extramedullary disease (not achieved vs. 3.7 months; odds ratio: 3.4; p<0.001). The median number of prior therapies was 3 (1-8). Initiation of DARA therapy in the early period provided an advantage for OS and PFS, although it was statistically insignificant. Infusion-related reactions were observed in 18 (13.4%) patients. All reactions occurred during the first infusion and most reactions were of grade 1 or 2 (94.5%). The frequency of neutropenia and thrombocytopenia was higher in the DARA-Rd group (61.9% vs. 24.7%, p<0.001 and 42.9% vs. 15.7%, p<0.001). Conclusion: Our study provides real-life data in terms of DARA therapy for patients with RRMM and supports the early initiation of DARA therapy. © 2023 by Turkish Society of Hematology Turkish Journal of Hematology.en_US
dc.identifier.doi10.4274/tjh.galenos.2023.2023.0029
dc.identifier.endpage250en_US
dc.identifier.issn1300-7777
dc.identifier.issue4en_US
dc.identifier.pmid37961952en_US
dc.identifier.scopus2-s2.0-85178660485en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage242en_US
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2023.2023.0029
dc.identifier.urihttps://hdl.handle.net/11454/101367
dc.identifier.volume40en_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Society of Hematologyen_US
dc.relation.ispartofTurkish Journal of Hematologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectDaratumumaben_US
dc.subjectReal-world dataen_US
dc.subjectRelapsed/refractory multiple myelomaen_US
dc.subjectdaratumumaben_US
dc.subjectdexamethasoneen_US
dc.subjectlenalidomideen_US
dc.subjectantineoplastic agenten_US
dc.subjectdaratumumaben_US
dc.subjectdexamethasoneen_US
dc.subjectthalidomideen_US
dc.subjectadulten_US
dc.subjectageden_US
dc.subjectanemiaen_US
dc.subjectArticleen_US
dc.subjectautologous stem cell transplantationen_US
dc.subjectcancer chemotherapyen_US
dc.subjectdiarrheaen_US
dc.subjectfemaleen_US
dc.subjecthematologic malignancyen_US
dc.subjecthumanen_US
dc.subjectmajor clinical studyen_US
dc.subjectmaleen_US
dc.subjectmonotherapyen_US
dc.subjectmulticenter studyen_US
dc.subjectmultiple cycle treatmenten_US
dc.subjectneuropathyen_US
dc.subjectneutropeniaen_US
dc.subjectoverall survivalen_US
dc.subjectpneumoniaen_US
dc.subjectprogression free survivalen_US
dc.subjectrelapsed refractory multiple myelomaen_US
dc.subjectrelapsed refractory multiple myelomaen_US
dc.subjectretrospective studyen_US
dc.subjectthrombocytopeniaen_US
dc.subjectvomitingen_US
dc.subjectclinical trialen_US
dc.subjectmultiple myelomaen_US
dc.subjectneutropeniaen_US
dc.subjectAntineoplastic Combined Chemotherapy Protocolsen_US
dc.subjectDexamethasoneen_US
dc.subjectFemaleen_US
dc.subjectHumansen_US
dc.subjectLenalidomideen_US
dc.subjectMaleen_US
dc.subjectMultiple Myelomaen_US
dc.subjectNeutropeniaen_US
dc.subjectRetrospective Studiesen_US
dc.subjectThalidomideen_US
dc.titleExperience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiyeen_US
dc.title.alternativeRelaps/Refrakter Multipl Myelomda Daratumumab Deneyemi: Türkiye’den Çok Merkezli Bir Çalışmaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu